Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid
- 1 September 1989
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 149 (9) , 1959-1961
- https://doi.org/10.1001/archinte.149.9.1959
Abstract
• Patients with thrombocytopenia have an increased risk of bleeding. We have used 18 courses of aminocaproic acid in 17 patients with either immune or nonimmune thrombocytopenia to successfully control hemorrhage associated with reduced platelet counts. The types of hemorrhage controlled included the following: vaginal, gastrointestinal, intracerebral, cutaneous, mucous membrane, subconjunctival, and renal, as well as that associated with dental extractions, tracheostomy, and sites of Penrose drains. The number of platelet and red blood cell transfusions administered decreased substantially following institution of aminocaproic acid therapy. We conclude that therapy with aminocaproic acid is safe and useful in the management of bleeding in patients with both immune and nonimmune thrombocytopenia. (Arch Intern Med.1989;149:1959-1961)This publication has 6 references indexed in Scilit:
- Reversal of coagulopathy in Kasabach‐Merritt syndrome with tranexamic acidScandinavian Journal of Haematology, 1986
- Anti‐fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patientsScandinavian Journal of Haematology, 1985
- Serial determinations of antiplatelet antibodies in a patient with Hodgkin's disease and autoimmune thrombocytopeniaCancer, 1983
- Myopathy associated with epsilon-aminocaproic acid (EACA) therapyJournal of Neurosurgery, 1978
- Thrombocytopenia Occurring During the Administration of HeparinAnnals of Internal Medicine, 1976
- MENINGOCOCCEMIA ASSOCIATED WITH INTRAVASCULAR COAGULATIONPediatrics, 1967